Participating Faculty

Supplements and Featured Publications, Managing Hepatitis C: Issues and Challenges for Managed Care, Volume 10, Issue 2 Suppl

This supplement to The American Journal of Managed Care contains information on hepatitis C, including prevalence, risk factors, complications, and treatment options.

Faculty

Bruce R. Bacon, MD

Professor of Internal Medicine

Saint Louis University School of Medicine

John G. McHutchison, MDAssociate Professor of Medicine

Duke Clinical Research Institute and

Duke University Medical Center

DISCLOSURE STATEMENT

It is policy at the University of Pennsylvania School of Medicine for faculty participating in continuing medical education activities to disclose to participants any significant financial interest or other relationship(s) maintained with a commercial company that has provided financial support for the activity, or whose products or services may be related to the subject matter of the educational content.

The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity with a full disclosure of the facts. It remains for participants to determine whether a faculty member's interest or relationships may have influenced the presentation in either the exposition or the conclusions presented.

The American Journal of Managed Care

It is policy at to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following faculty have reported receiving something of value* from the commercial supporter(s) of this activity or from a corporate organization whose product(s) may have relevance to the content of their presentations:

  • Amgen
  • Isis
  • Schering-Plough Serono International
  • Amgen
  • Genetrol Biotherapeutics
  • Maxim Novartis Metaphore
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Roche Schering-Plough

Speakers' Bureau For:

  • Akros Pharma Gilead Sciences Schering-Plough
  • Akros Pharma
  • Bayer
  • Bristol-Myers Squibb
  • Genprobe
  • IDUN
  • Ortho Diagnostic Systems
  • Ribozyme
  • Schering-Plough
  • Triange Vertex
  • Amgen
  • Centocor
  • InterMune
  • National Genetics Institute
  • Pfizer
  • Ribozyme Schering-Plough

Speakers' Bureau For:

  • InterMune Roche Schering-Plough

Investigational and/or Off-Label Use of Commercial Products and Devices

The University of Pennsylvania School of Medicine requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside Food and Drug Administration—approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

The following information was provided by the faculty:

Faculty: Bruce R. Bacon, MDProduct: Interferon

Product: Interferon

*Something of value refers to any equity position, receipt of royalties/honoraria, funding of a research grant, consultations, or to any other relationship with a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policies.